NASDAQ:ARLZ - Aralez Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.03 -0.01 (-25.00 %) (As of 08/21/2018 01:53 AM ET)Previous Close$0.04Today's Range$0.02 - $0.0452-Week Range$0.02 - $2.98Volume6.75 million shsAverage Volume1.61 million shsMarket Capitalization$3.79 millionP/E Ratio-0.03Dividend YieldN/ABeta1.2 Company ProfileAnalyst RatingsChartDividend HistoryEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada. Receive ARLZ News and Ratings via Email Sign-up to receive the latest news and ratings for ARLZ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:ARLZ CUSIP73941U10 Webwww.aralez.com Phone905-876-1118 Debt Debt-to-Equity Ratio-41.79 Current Ratio0.80 Quick Ratio0.75 Price-To-Earnings Trailing P/E Ratio-0.03 Forward P/E Ratio-0.04 P/E GrowthN/A Sales & Book Value Annual Sales$105.95 million Price / Sales0.02 Cash FlowN/A Price / CashN/A Book Value$0.23 per share Price / Book0.13 Profitability EPS (Most Recent Fiscal Year)($1.20) Net Income$-125,200,000.00 Net Margins-99.50% Return on Equity-271.44% Return on Assets-20.46% Miscellaneous Employees164 Outstanding Shares67,190,000Market Cap$3.79 million Aralez Pharmaceuticals (NASDAQ:ARLZ) Frequently Asked Questions What is Aralez Pharmaceuticals' stock symbol? Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ." How were Aralez Pharmaceuticals' earnings last quarter? Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced its earnings results on Thursday, November, 9th. The company reported ($0.37) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.02. The company had revenue of $24.30 million for the quarter, compared to analysts' expectations of $22.87 million. Aralez Pharmaceuticals had a negative net margin of 99.50% and a negative return on equity of 271.44%. The business's revenue for the quarter was up 78.7% on a year-over-year basis. During the same period last year, the firm earned ($0.32) earnings per share. View Aralez Pharmaceuticals' Earnings History. When is Aralez Pharmaceuticals' next earnings date? Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 22nd 2018. View Earnings Estimates for Aralez Pharmaceuticals. What price target have analysts set for ARLZ? 3 analysts have issued twelve-month price objectives for Aralez Pharmaceuticals' stock. Their predictions range from $6.00 to $6.00. On average, they expect Aralez Pharmaceuticals' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 19,900.0% from the stock's current price. View Analyst Price Targets for Aralez Pharmaceuticals. What is the consensus analysts' recommendation for Aralez Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aralez Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aralez Pharmaceuticals. Who are some of Aralez Pharmaceuticals' key competitors? Some companies that are related to Aralez Pharmaceuticals include Citius Pharmaceuticals (CTXR), Sonoma Pharmaceuticals (SNOA), Pulmatrix (PULM), IntelliPharmaCeutics Intl (IPCI), THERAPIX BIOSCI/S (TRPX), Dare Bioscience (DARE), Sunwin Stevia International (SUWN), Parnell Pharmaceuticals (PARNF), Flex Pharma (FLKS), DelMar Pharmaceuticals (DMPI), Ritter Pharmaceuticals (RTTR), Mabvax Therapeutics (MBVX), Endonovo Therapeutics (ENDV), Amarillo Biosciences (AMAR) and Jaguar Health (JAGX). Who are Aralez Pharmaceuticals' key executives? Aralez Pharmaceuticals' management team includes the folowing people: Mr. Adrian Adams, CEO & Director (Age 67)Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)Mr. Michael Kaseta, Chief Financial Officer (Age 42)Dr. James Patrick Tursi, Chief Medical Officer (Age 53)Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68) Has Aralez Pharmaceuticals been receiving favorable news coverage? News coverage about ARLZ stock has been trending somewhat positive on Monday, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aralez Pharmaceuticals earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news stories about the company an impact score of 48.09 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Aralez Pharmaceuticals. Who are Aralez Pharmaceuticals' major shareholders? Aralez Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Salzhauer Michael (0.74%). Company insiders that own Aralez Pharmaceuticals stock include Adrian Adams, Andrew I Koven, Arthur S Kirsch, Eric Trachtenberg, James Patrick Tursi, Jason Aryeh, Kenneth B Lee Jr, Mark A Glickman, Robert Paul Harris, Scott J Charles and Seth Rudnick. View Institutional Ownership Trends for Aralez Pharmaceuticals. Which institutional investors are buying Aralez Pharmaceuticals stock? ARLZ stock was bought by a variety of institutional investors in the last quarter, including Salzhauer Michael. Company insiders that have bought Aralez Pharmaceuticals stock in the last two years include Adrian Adams, Arthur S Kirsch, James Patrick Tursi, Kenneth B Lee Jr and Seth Rudnick. View Insider Buying and Selling for Aralez Pharmaceuticals. How do I buy shares of Aralez Pharmaceuticals? Shares of ARLZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aralez Pharmaceuticals' stock price today? One share of ARLZ stock can currently be purchased for approximately $0.03. How big of a company is Aralez Pharmaceuticals? Aralez Pharmaceuticals has a market capitalization of $3.79 million and generates $105.95 million in revenue each year. The company earns $-125,200,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Aralez Pharmaceuticals employs 164 workers across the globe. How can I contact Aralez Pharmaceuticals? Aralez Pharmaceuticals' mailing address is 7100 WEST CREDIT AVENUE SUITE 101, MISSISSAUGA A6, L5N 0E4. The company can be reached via phone at 905-876-1118 or via email at [email protected] MarketBeat Community Rating for Aralez Pharmaceuticals (NASDAQ ARLZ)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 199 (Vote Outperform)Underperform Votes: 193 (Vote Underperform)Total Votes: 392MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARLZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARLZ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?